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pathophysiological basis of KOA is multifaceted and includes impaired
muscle function, reduced proprioceptive acuity, and the psychological
traits of chronic pain. Tai Chi is an ancient Chinese exercise that uses
an integrated mind-body approach to enhance muscle function, balance,
ﬂexibility, and reduce pain, depression and anxiety. Tai Chi may thus be
especially suited to the therapy of KOA.
Methods: We used a random number list to randomize 40 eligible indi-
viduals (age >55 yr, BMI 40 kg/m2 with knee pain on most days of the
previous month and tibiofemoral OA K/L grade 2) to Tai Chi (10 modiﬁed
forms from classical Yang style) or an attention control (stretching and
wellness education). The 60-minute intervention sessions occurred twice-
weekly for 12 weeks. The primary endpoint was change in the WOMAC
pain score (VAS) at 12 weeks. Secondary endpoints included WOMAC
function, patient and physician global assessments (VAS), timed chair
stand, balance tests, knee proprioception (Biometrics electrogoniometer),
depression (CES-D index), self-efﬁcacy, and health-related quality of life
(SF-36). We repeated these assessments at 24 and 48 weeks to test
durability of response. The Tai Chi and control groups were compared by
intention-to-treat using t-tests.
Table. Changes in primary and secondary outcomes
Variables Groups* Baseline At 12 week
Change
(95%CI)
P-Value
for D
between
group***
WOMAC-Pain VAS, 0–500mm Tai Chi 209.3
(58.5)
−157.3
(−198.5, −116)
0.0004
Control 220.4
(101)
−38.5
(−87.2, 10.3)
WOMAC-Physical function VAS, 0–1700mm Tai Chi 707.6
(246.9)
−506.8
(−635.5, −378)
0.001
Control 827.0
(258.8)
−182.2
(−321.8, −42.5)
Patient Global VAS, 1−10 cm Tai Chi 4.2
(2.1)
−3.0
(−3.9, −2.0)
0.003
Control 4.8
(2.0)
−0.8
(−1.9, 0.2)
Physician Global VAS, 1−10 cm Tai Chi 4.8
(1.7)
−3.1
(−3.9, −2.4)
0.0009
Control 5.8
(2.2)
−1.4
(−2.1, −0.8)
Chair stand test (sec) Tai Chi 40.8
(13.4)
−12.0
(−16.7, −7.4)
0.0005
Control** 35.6
(9.2)
−0.9
(−4.8, 3.0)
Proprioception (30 degree) Tai Chi 5.6
(4.2)
−2.5
(−5.0, −0.01)
0.01
Control** 4.3
(2.9)
2.1
(−0.6, 4.8)
Self efﬁcacy (0−25) Tai Chi 3.1
(1.1)
0.6
(−0.01, 1.2)
0.05
Control 3.3
(0.9)
−0.1
(−0.5, 0.3)
SF-36: PCS (0−50) Tai Chi 37.5
(8.5)
11.6
(7.6, 15.5)
0.005
Control 32.0
(8.8)
4.1
(0.7, 7.5)
SF-36: MCS (0−50) Tai Chi 51.4
(12.2)
2.1
(−4.0, 8.3)
1.0
Control 50.8
(12.6)
1.9
(−2.6, 6.5)
CES-D (0−60) Tai Chi 13.6
(11.7)
−7.4
(−11.4, −3.4)
0.009
Control 9.3
(9.2)
−0.7
(−3.9, 2.5)
*N=20 for each group. **N=19. ***Signiﬁcant improvement of Tai Chi versus attention control at
week 12. CES-D = the Center for Epidemiology Studies Depression index, SF-36 (PCS) = Short-
Form health survey (physical component summary), SF-36 (MCS) = Short-Form health survey
(mental component summary), VAS = Visual Analogue Scale.
Results: The participants had mean age 65 y (SD 7.8), mean disease
duration 10 y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and out-
come measures. Participants’ baseline expectations of beneﬁt from an
exercise intervention were also similar between the two groups [outcome
expectations for exercise score for Tai Chi = 4.1 (SD 0.6), controls = 4.3
(SD 0.4)]. Attendance for the 12-week assessment was 85% in the Tai
Chi group and 89% in the attention control. Participants in the Tai Chi arm
exhibited signiﬁcantly greater improvements in pain, physical function, de-
pression, self-efﬁcacy and health status (Table). Patients who continued
Tai Chi practice after 12 weeks reported durable beneﬁts in WOMAC pain
[between-group difference −150.2 (SD 116.6), p=0.04 at week 24 and
−185.3 (SD 54.1), p=0.001 at week 48] and WOMAC function [between-
group difference −572.7 (SD 257.8), p=0.02 at week 48].
Conclusions: Tai Chi is efﬁcacious for treatment of pain and physical
impairment in people with severe KOA. Further studies should be per-
formed to replicate these results and deepen our understanding of this
therapeutic modality.
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Purpose: To assess the prevalence of osteoarthritis and medication
use among participants in a population-based cohort study conducted
in Australia.
Methods: The North West Adelaide Health Study is a representative
longitudinal cohort study of people aged 18 years and over living in
the northwest region of Adelaide, South Australia, Australia. The original
sample (n = 4060) was randomly selected and recruited by telephone
interview to participate in a clinic assessment. The second stage of
data collection from this cohort was undertaken between mid 2004 and
early 2006 and in this phase, information regarding the prevalence of
musculoskeletal conditions was included. The self reported prevalence
of arthritis (including osteoarthritis) was collected using a Computer As-
sisted Telephone Interview (CATI) survey. All medications that participants
were taking, including complementary and alternative medicines, were
recorded at the clinic visit.
Results: Overall, n = 3502 participants responded to the CATI component
of the study, with 7.5% (95% CI 6.6−8.4) reporting that they had been told
by a doctor that they had osteoarthritis. There was also 10.8% (95% CI
9.8−11.8) of respondents who reported that they did not know the type
of arthritis that they had. Among respondents who stated that they had
osteoarthritis, 22.3% (95% CI 17.4−28.1) were on COX-2 inhibitors and
11.0% (95% CI 7.6−15.6) were on a non steroidal anti-inﬂammatory
medication (NSAID, excluding aspirin). There were also 20.6% (95% CI
15.9−26.3) with osteoarthritis who reported that they took aspirin. Of the
respondents with osteoarthritis who took a non-selective NSAID there
were 11.2% who also took a COX-2 inhibitor and among the respondents
who took a non-selective NSAID (excluding aspirin) and/or a selective
NSAID (COX-2 inhibitor), a quarter (24.6%) also took aspirin, 7.4% took
alendronate and 3.2% took metformin. Of those with osteoarthritis and
taking any form of NSAID (excluding aspirin), 37.6% were also taking
proton pump inhibitors which might suggest gastroesophageal problems
and 37.9% had renal disease (using the Cockcroft-Gault equation to cal-
culate the glomerular ﬁltration rate (GFR), with renal disease deﬁned as
an estimated GFR of less than 60mL/min per 1.73m2). Respondents self-
reporting that they had osteoarthritis also took a variety of complementary
and alternative medicines. Overall, 13.7% (95% CI 9.9−18.8) took ﬁshoil
and 20.0% (95% CI 15.4−25.6) took glucosamine and/or chondroitin.
Conclusions: Medication is an important part of arthritis treatment and
fracture prevention, but even in those whose doctor had told them
they had arthritis, in particular osteoarthritis, opportunities to use anti-
inﬂammatory medications were missed or inappropriate medications were
used in conjunction with these drugs.
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Purpose: Osteoarthritis (OA) is characterized as a heterogeneous disor-
der with evidence of multigenic inheritance. Previous studies have identi-
ﬁed several candidate genes as well as novel loci on chromosomes 2, 7,
11 and 16 associated with OA at the hand, hip, knee and/or spine. The
goal of the Genetics of Generalized Osteoarthritis (GOGO) Study was
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to identify regions associated with increased susceptibility to generalized
OA.
Methods: A total of 2728 subjects from 1145 pedigrees were enrolled at
seven academic sites in the US and UK. A qualifying pedigree consisted
of at least two affected sibs with clinical hand OA who were of self-
reported Caucasian ethnicity. Individuals were subsequently classiﬁed as
having hand, hip, knee and/or spine OA based on prespeciﬁed radio-
graphic criteria (see OA Cart 2006;15:120−7 for case deﬁnitions). A total
of 2148 subjects from 880 families were genotyped using the deCODE
4cM Genome Wide Scan marker set (deCODE Genetics, Reykjavik,
Iceland), that consists of 1115 short sequence repeat (SSR) microsatellite
markers distributed at an average density of 1 SSR marker per 4 cM over
all 22 autosomes and the two sex chromosomes. For the high-density
association (HDA) analysis, 786 siblings with multiple-joint OA from 533
nuclear families (330 families with one affected sibling and 203 families
with more than one affected sibling) and 511 unaffected controls from the
Genetics of Osteoarthritis (GO) study, a genetic association study using
identical phenotypic procedures and deﬁnitions, were selected for SNP
typing. The genome wide linkage scan was analyzed using MERLIN; for
the HDA analysis, tests for genotypic and allelic association were applied
to each marker.
Results: Overall, LOD scores >2 were observed for six chromosome
and phenotype pairs (ﬁve chromosomes [2, 10, 18, 20, and X] and
three phenotypes [hand CMC, hand PIP, and knee OA]) (see Table). The
highest LOD score was 3.01 on chromosome 2 at 123.0 cM for hand PIP.
The next highest LOD score was 2.41 on chromosome 18 at 66.6 cM,
region 18q21, for knee OA. Owing to the comparative lack of information
regarding OA susceptibility for the chromosome 18 region, a HDA analysis
was conducted on 18q21. Of the 1797 SNPs tested, 151, 162, 134,
133 and 135 showed evidence of association (P< 0.05 for the allelic or
genotypic test) with hand OA, hand DIP OA, hand PIP OA, knee OA, and
spine OA, respectively; 28 of these SNPs showed consistent association
(P< 0.05) with all ﬁve OA phenotypes. Two SNPs within gene APM-1
(Adipose most abundant gene transcript 1) showed strong association
(P< 0.01) with hand and knee OA, while strong associations were also
observed within gene WDR7 (WD repeat domain 7 [alias TRAG, TGF-B
resistance associated gene]) for hand OA (P< 0.01), genes DCC (Deleted
in colorectal cancer [aliases CRC18, CRCR1]) and TXNL1 (thioredoxin-
like 1 [alias TRP32]) (P< 0.001) for knee OA, and within gene LOC390858
(P< 0.001) for spine OA.
Conclusions: These data extend results of previous genome wide link-
age scans that have identiﬁed chromosome 2 and implicate genes in a
new area of chromosome 18 as being associated with generalized OA.
Chromosome Regions with LOD Scores >2.0 on Genome Wide Linkage Scan, The GOGO Study
Chromosome Location (cM) One LOD drop interval (cM) OA Phenotype LOD Score
2 158.0 148.0–187.0 Hand CMC 2.16
2 123.0 117.0–129.0 Hand PIP 3.01
10 Telomere 0.0−9.2 Hand CMC 2.04
18 66.6 60.1−86.1 Knee OA 2.41
20 40.0 33.0−46.0 Hand CMC 2.17
X 153.2 132.2–163.2 Hand PIP 2.13
X 158.7 149.2–161.2 Hand CMC 2.19
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Purpose: There continues to be a need for reliable markers to predict
which osteoarthritis (OA) patients will experience disease progression.
Previous studies have suggested that inﬂammation may be important in
the pathogenesis and progression of OA. We performed a study in sub-
jects with knee OA to investigate selected candidate gene polymorphisms
for associations with radiographic severity.
Methods: One hundred thirty OA patients with knee OA from two
separate study center databases (New York Hospital for Joint Diseases;
NYUHJD, N=80 and Duke University Medical Center, N=50) met inclu-
sion criteria in this cross-sectional retrospective analysis. Caucasians of
either sex, free of chronic disease, with a radiographic diagnosis of knee
OA were genotyped for single nucleotide polymorphisms (SNPs). These
subjects were divided into two groups: one having index knee Kellgren-
Lawrence (KL) scores of one or two, and the other, KL scores of three or
four. A subset (NYUHJD) with available data (N=36) was separated by
joint space width (JSW) either above or below the median. We performed
statistical analysis using Chi square and Fisher’s exact test, and logistic
regression, adjusting for age, gender and BMI to evaluate associations
of radiographic severity with individual SNPs and with haplotypes.
Results: After adjustment for age, gender, and BMI, individual IL1
receptor antagonist (IL1RN) SNPs were strongly associated with KL
radiographic severity and joint space width (JSW; Table 1). The KL results
were conﬁrmed separately in NYUHJD and Duke cohorts. Also, carriage
of either one or two copies of a haplotype consisting of (ACT): IL1RN
rs9005, IL1RN rs419598, IL1RN rs315952 (haplotype frequency in this
OA study 25−32%) was associated with a substantially decreased risk of
radiographic severity (OR 0.16; 95%CI 0.06−0.40), and with JSW above
the median (OR 25.4; 95% CI 1.59–404.2) compared to the remaining
68−75% of the OA population.
Table 1: Association of SNPs with radiographic severity
Genotypes KL score> 2 (N=130) JSW<median (N=36)
SNP genotype freq p OR (95%CI) p OR (95%CI)
IL1RN rs9005 GG 55% <0.0001 8.59 (3.64−20.28) 0.007 14.5 (2.05–103.1)
AA/AG 45% 1.0 1.0
IL1RN rs419598 TT 65% <0.0001 5.45 (2.27−13.09) 0.016 28.7 (1.86–445.0)
CC/CT 35% 1.0 1.0
IL1RN rs315952 CC/CT 47% 0.027 2.79 (1.33−5.86) NS NS
TT 52% 1.0
Conclusions: IL1RN SNPs are associated with radiographic severity in
OA, and may predict the potential for radiographic severity and progres-
sion. These genetic markers may be useful for the medical management
of OA, and also as a tool to enrich for subjects who progress radiograph-
ically in clinical trials of DMOADs.
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Purpose: Lumbar degenerative disc disease (LDD) is a major cause
of back pain which is a considerable public health problem in Western
countries. Back pain is a common cause of work absenteeism and the
prevalence is increasing. LDD is known to be inﬂuenced by genetic
factors, with estimated heritability >70%. Little is known, however, of the
pathogenic processes underlying the development of degenerate discs. A
number of genetic loci, including polymorphisms within COL 9, VDR and
certain inﬂammation-related genes, have been shown to be associated
with LDD. LDD has much in common with osteoarthritis (OA) at the
knee: the pathophysiological changes are similar in cartilage and disc,
the conditions have genes in common and progression at the knee is
predicted by LDD. In the present study, we sought to identify novel genetic
determinants of LDD by examining single nucleotide polymorphisms
(SNPs) which had previously been found associated with knee OA.
Methods: Two population based cohorts were used in this study, TwinsUK
and the Chingford Study. All participants gave written consent and ethics
committee approval was obtained. Female participants in the Chingford
study (n = 670) underwent plain radiography with standard lateral lumbar
spine ﬁlm. LDD was scored using a 4-point scale for disc space narrow-
ing (DSN) and anterior osteophytes (AO). Female twins (n = 291) from
the TwinsUK cohort were selected who had previously undergone T2-
weighted sagittal MRI scanning of the lumbar spine. The scans had been
coded for degenerative change using a 4-point scale at each of: DSN,
disc signal intensity, disc bulge and AO. A cumulative overall score for
LDD was derived by summing the 4-point scale for the 4 features over
all the lumbar disc levels. A panel of 28 SNPs derived from a genome
wide scan (GWS) of knee OA was used. These were tested initially in
women from the Chingford study, and the top SNP was carried through to
a replication group from TwinsUK. Work was carried out using software
packages R and Helixtree.
Results: After adjustment for age and body mass index, only one SNP
of the 28 identiﬁed in the knee OA GWS was associated with both
DSN (p< 0.004) and AO (p< 0.007) in the Chingford Study participants.
Individuals carrying one or two copies of the G allele (minor allele
frequency = 25%) had an 11% higher AO grade and 18% higher DSN
grade. This SNP was subsequently found to be associated with the
overall score for LDD in the TwinsUK participants (p< 0.04). In particular,
